UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~January~~April 3130, 2024

Commission File Number: 000-55862

BAKHU HOLDINGS, CORP.

(Exact name of Registrant as specified in its charter)

Nevada		26-0510649
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

One World Trade Center, Suite 130, Long Beach, California 90831

(Address of principal executive offices, Zip Code)

(858) 682-2548

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbols(s)

Name of each exchange on which registered

N/A

As of ~~March~~June 2512, 2024, the Registrant had 301,302,983 shares of Common Stock outstanding.

Page 1

TABLE OF CONTENTS

PART I: FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3:	Quantitative and Qualitative Disclosures about Market Risk	20
Item 4:	Controls and Procedures	20
PART II: OTHER INFORMATION
Item 1:	Legal Proceedings	21
Item 1A:	Risk Factors	21
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3:	Defaults Upon Senior Securities	21
Item 5:	Other Information	21
Item 6:	Exhibits	2425

Page 2

PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BAKHU HOLDINGS, CORP.

Consolidated Balance Sheets

(Unaudited)

ASSETS
	January 31,	July 31,
	April 30,	July 31,
	2024	2023
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$~~426~~81,~~347~~519	$3,101
Total Current Assets	426,347	3,101
Prepaid expenses	70,361	-
Total Current Assets	151,880	3,101
OTHER ASSETS
Fixed assets, net of accumulated depreciation of $267,343 and $200,507, respectively	401,015	467,850
Fixed assets, net of accumulated depreciation of $300,761 and $200,507, respectively	367,597	467,850
Total Other Assets	~~401~~367,~~015~~597	467,850
TOTAL ASSETS	$~~827~~519,~~362~~477	$470,951
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued liabilities	$21,~~009~~958,~~943~~156	$2,639,281
Accrued interest	~~553~~565,~~452~~364	412,813
Settlement liability due to leasing company	260,000	-
Notes payable - related parties current portion	150,000	6,744,672
Total Current Liabilities	2,~~973~~933,~~395~~520	9,796,766
NON-CURRENT LIABILITIES
Notes payable – related parties	7,~~103~~160,~~972~~046	-
Notes payable – third parties	~~530~~653,~~000~~770	-
Total Non-Current Liabilities	7,~~633~~813,~~972~~816	-
TOTAL LIABILITIES	10,~~607~~747,~~367~~336	9,796,766
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 and 4 shares of Series A Preferred Stock issued and outstanding, respectively	-	-
Common stock, $0.001 par value; 500,000,000 shares authorized, 301,302,983 and 301,302,983 shares issued and outstanding, respectively	301,303	301,303
Additional paid-in capital	3839,~~650~~109,~~338~~321	37,852,370
Accumulated deficit	(4849,~~731~~638,~~646~~483)	(47,479,488)
Total Stockholders' Equity (Deficit)	(910,~~780~~227,~~005~~859)	(9,325,815)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$~~827~~519,~~362~~477	$470,951

The accompanying notes are an integral part of these financial statements

Page 3

BAKHU HOLDINGS, CORP.

Consolidated Statements of Operations

(Unaudited)

	~~For the Three Months Ended~~		For the Three Months Ended
	January 31,
			April 30,
	~~2024~~		~~2023~~2024	2023
			~~(As Restated – see Note 9)~~	(As Restated – see Note 9)
NET REVENUES	$-		$-	$-
OPERATING EXPENSES
Consulting fees (including stock-based compensation of $170,993 and $2,569,241, respectively) (as restated for the three months ended January 31, 2023 – see Note 9)	171,254		2,644,812
Consulting fees (including stock-based compensation of $458,983 and $1,713,675, respectively) (as restated for the three months ended April 30, 2023 – see Note 9)			468,484	1,779,670
Professional fees	~~2,472~~		~~178~~87,~~495~~675	52,008
Depreciation of fixed assets	~~33,418~~		33,418	33,418
Other operating expenses	~~160,086~~		~~233~~228,~~408~~344	229,700
Total Operating Expenses (as restated for the three months ended January 31, 2023 – see Note 9)	367,230		3,090,133
Total Operating Expenses (as restated for the three months ended April 30, 2023 – see Note 9)			817,921	2,094,796
LOSS FROM OPERATIONS (as restated for the three months ended January 31, 2023 – see Note 9)	(367,230)		(3,090,133)
LOSS FROM OPERATIONS (as restated for the three months ended April 30, 2023 – see Note 9)			(817,921)	(2,094,796)
OTHER INCOME (EXPENSES)
Gain on settlement of debt	~~323,078~~	-	-		-
Interest expense	(76,528)		(48,830)
Loss on sale of equipment		-			-
Total Other Income (Expenses)	246,550		(48,830)
Interest expense			(88,916)	(48,037)
LOSS BEFORE INCOME TAXES (as restated for the three months ended January 31, 2023 – see Note 9)	(120,680)		(3,138,963)
Total Other Income (Expenses)			(88,916)	(48,037)
PROVISION FOR INCOME TAXES	-		-
LOSS BEFORE INCOME TAXES (as restated for the three months ended April 30, 2023 – see Note 9)			(906,837)	(2,142,833)
NET LOSS (as restated for the three months ended January 31, 2023 – see Note 9)	$(120,680)		$(3,138,963)
PROVISION FOR INCOME TAXES			-	-
BASIC AND DILUTED NET LOSS PER COMMON SHARE (as restated for the three months ended January 31, 2023 – see Note 9)	$(0.00)		$(0.01)
NET LOSS (as restated for the three months ended April 30, 2023 – see Note 9)			$(906,837)	$(2,142,833)
WEIGHTED AVERAGE NUMBER OF COMMON
BASIC AND DILUTED NET LOSS PER COMMON SHARE (as restated for the three months ended April 30, 2023 – see Note 9)			$(0.00)	$(0.01)
SHARES OUTSTANDING - BASIC AND DILUTED	301,302,983		301,298,200
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING - BASIC AND DILUTED			301,302,983	301,302,983

The accompanying notes are an integral part of these financial statements

Page 4

BAKHU HOLDINGS, CORP.

Consolidated Statements of Operations (Continued)

(Unaudited)

	For the Six Months Ended
	For the Nine Months Ended
	January 31,
	April 30,
	2024	2023
		(As Restated – see Note 9)
NET REVENUES	$-	$-
OPERATING EXPENSES
Consulting fees (including stock-based compensation of $797,968 and $5,640,211, respectively) (as restated for the six months ended January 31, 2023 – see Note 9)	863,860	5,810,899
Consulting fees (including stock-based compensation of $1,256,951 and $7,353,885, respectively) (as restated for the nine months ended April 30, 2023 – see Note 9)	1,332,344	7,590,569
Professional fees	~~194~~282,~~798~~473	~~348~~400,~~718~~726
Depreciation of fixed assets	66100,~~836~~254	66100,~~836~~254
Other operating expenses	~~309~~537,~~103~~447	~~523~~753,~~922~~622
Total Operating Expenses (as restated for the six months ended January 31, 2023 – see Note 9)	1,434,597	6,750,375
Total Operating Expenses (as restated for the nine months ended April 30, 2023 – see Note 9)	2,252,518	8,845,171
LOSS FROM OPERATIONS (as restated for the six months ended January 31, 2023 – see Note 9)	(1,434,597)	(6,750,375)
LOSS FROM OPERATIONS (as restated for the nine months ended April 30, 2023 – see Note 9)	(2,252,518)	(8,845,171)
OTHER INCOME (EXPENSES)
Gain on settlement of debt	323,078	-
Loss on sale of equipment	-	(65,748)
Interest expense	(~~140~~229,~~639~~555)	(95143,~~493~~530)
Total Other Income (Expenses)	~~182~~93,~~439~~523	(~~161~~209,~~241~~278)
LOSS BEFORE INCOME TAXES (as restated for the six months ended January 31, 2023 – see Note 9)	(1,252,158)	(6,911,616)
LOSS BEFORE INCOME TAXES (as restated for the nine months ended April 30, 2023 – see Note 9)	(2,158,995)	(9,054,449)
PROVISION FOR INCOME TAXES	-	-
NET LOSS (as restated for the six months ended January 31, 2023 – see Note 9)	$(1,252,158)	$(6,911,616)
NET LOSS (as restated for the nine months ended April 30, 2023 – see Note 9)	$(2,158,995)	$(9,054,449)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (as restated for the six months ended January 31, 2023 – see Note 9)	$(0.00)	$(0.02)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (as restated for the nine months ended April 30, 2023 – see Note 9)	$(0.01)	$(0.03)
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING - BASIC AND DILUTED	301,302,983	301,~~290~~294,~~592~~722

The accompanying notes are an integral part of these financial statements

Page 5

BAKHU HOLDINGS, CORP.

Consolidated Statements of Cash Flows

(Unaudited)

	For the Six Months Ended
	For the Nine Months Ended
	January 31,
	April 30,
	2024	2023
		(As Restated – see Note 9)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss (as restated for the six months ended January 31, 2023 – see Note 9)	$(1,252,158)	$(6,911,616)
Net loss (as restated for the nine months ended April 30, 2023 – see Note 9)	$(2,158,995)	$(9,054,449)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock based compensation (as restated for the six months ended January 31, 2023 – see Note 9)	797,968	5,640,211
Stock based compensation (as restated for the nine months ended April 30, 2023 – see Note 9)	1,256,951	7,353,886
Gain on settlement of debt	(323,078)	-
Loss on sale of equipment	-	65,748
Depreciation of fixed assets	66100,~~836~~254	66100,~~836~~254
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	(306,260)	719,664
Prepaid expenses	(70,361)	-
Accrued interest	140,639	95,493
Accounts payable and accrued liabilities	(358,047)	1,013,570
Accrued interest	227,894	143,531
Settlement liability due to leasing company	260,000	-
Net Cash Used in Operating Activities	(~~616~~1,~~054~~065,382)	(~~323~~377,~~664~~460)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of equipment	-	10,125
Net Cash Provided by Investing Activities	-	10,125
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock	-	30,000
Proceeds from notes payable – third parties	~~530~~625,000	-
Payments on notes payable - related parties	-	(2,883)
Proceeds from notes payable - related parties	~~509~~518,~~300~~800	~~276~~328,~~372~~336
Net Cash Provided by Financing Activities	1,~~039~~143,~~300~~800	~~303~~355,~~489~~453
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	~~423~~78,~~246~~418	(1011,~~050~~882)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,101	12,451
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$~~426~~81,~~347~~519	$~~2,401~~569
SUPPLEMENTAL DISCLOSURES:
Cash Payments For:
Interest	$-1,660	$-
Income taxes	$-	$-
Noncash investing and financing activities:
Accrued interest added to principal of Convertible Senior Secured
Promissory Notes due February 26, 2028	$75,344	$-

The accompanying notes are an integral part of these financial statements

Page 6

BAKHU HOLDINGS, CORP.

Consolidated Statements of Stockholders' Equity (Deficit)

(Unaudited)

	Six Months Ended January 31, 2024
	Nine Months Ended April 30, 2024
					Additional		Total
	Preferred Stock		Common Stock		Paid-In	Accumulated	Stockholders'
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance, July 31, 2023	4	$-	301,302,983	$301,303	$37,852,370	$(47,479,488)	$(9,325,815)
Vesting of stock options and warrants	-	-	-	-	626,975	-	626,975
Cancellation of Preferred Stock	(4)	-	-	-	-	-	-
Net loss for the three months ended
October 31, 2023	-	-	-	-	-	(1,131,478)	(1,131,478)
Balance, October 31, 2023	-	-	301,302,983	301,303	38,479,345	(48,610,966)	(9,830,318)
Vesting of stock options and warrants	-	-	-	-	170,993	-	170,993
Net loss for the three months ended
January 31, 2024	-	-	-	-	-	(120,680)	(120,680)
Balance, January 31, 2024	-	$-	301,302,983	$301,303	$38,650,338	$(48,731,646)	$(9,780,005)
Vesting of stock options and warrants	-	-	-	-	458,983	-	458,983
Net loss for the three months ended
April 30, 2024	-	-	-	-	-	(906,837)	(906,837)
Balance, April 30, 2024	-	$-	301,302,983	$301,303	$39,109,321	$(49,638,483)	$(10,227,859)

The accompanying notes are an integral part of these financial statements

Page 7

BAKHU HOLDINGS, CORP.

Consolidated Statements of Stockholders' Equity (Deficit) (continued)

(Unaudited)

	Six Months Ended January 31, 2023
	Nine Months Ended April 30, 2023
					Additional		Total
	Preferred Stock		Common Stock		Paid-In	Accumulated	Stockholders'
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance, July 31, 2022 (as restated – see Note 9)	4	$-	301,282,983	$301,283	$29,715,228	$(37,174,034)	$(7,157,523)
Vesting of stock options and warrants (as restated – see Note 9)	-	-	-	-	3,070,970	-	3,070,970
Net loss for the three months ended
October 31, 2022 (as restated – see Note 9)	-	-	-	-	-	(3,772,653)	(3,772,653)
Balance, October 31, 2022 (as restated – see Note 9)	4	-	301,282,983	301,283	32,786,198	(40,946,687)	(7,859,206)
Vesting of stock options and warrants (as restated – see Note 9)	-	-	-	-	2,569,241	-	2,569,241
Stock issued for cash	-	-	20,000	20	29,980	-	30,000
Net loss for the three months ended
January 31, 2023 (as restated – see Note 9)	-	-	-	-	-	(3,138,963)	(3,138,963)
Balance, January 31, 2023 (as restated – see Note 9)	4	$-	301,302,983	$301,303	$35,385,419	$(44,085,650)	$(8,398,928)
Vesting of stock options and warrants (as restated – see Note 9)	-	-	-	-	1,713,675	-	1,713,675
Net loss for the three months ended
April 30, 2023 (as restated – see Note 9)	-	-	-	-	-	(2,142,833)	(2,142,833)
Balance, April 30, 2023 (as restated – see Note 9)	4	$-	301,302,983	$301,303	$37,099,094	$(46,228,483)	$(8,828,086)

The accompanying notes are an integral part of these financial statements

Page 8

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS; BASIS OF PRESENTATION

Bakhu Holdings, Corp. (formerly Planet Resources, Corp.) (the “Company”) was incorporated under the laws of the State of Nevada, U.S. on April 24, 2008. In May 2009, the Company began to look for other types of business to pursue that would benefit the stockholders. To pursue businesses outside the mining industry the name of the Company was changed with the approval of the directors and stockholders to Bakhu Holdings, Corp. on May 4, 2009.

The Company has not generated any revenue to date, and consequently, its operations are subject to all risks inherent in establishing a new business enterprise. For the period from inception, April 24, 2008, through ~~January~~April 3130, 2024, the Company has accumulated losses of $4849,~~731~~638,~~646~~483.

On December 20, 2018, the Company acquired a license from Cell Science Holding Ltd. (“Cell Science”) in exchange for 210,000,000 shares of Company common stock. The license provides for the Company’s exclusive right in North America and Central America to use certain patents and intellectual property for the production of cannabinoids for medical, food additive, and recreational uses.

On August 9, 2019, the Company formed Cell Science CBD International, Inc., a California corporation as a wholly owned subsidiary to commercialize use of the licensed technology to produce and manufacture cannabis and their byproducts that have measurable tetrahydrocannabinol (THC) concentration potency less than 3% on a dry weight basis. This subsidiary had no active operations as of ~~January~~April 3130, 2024. When used herein, the “Company” includes this consolidated subsidiary.

In the opinion of management, the Company’s financial statements reflect all adjustments that are of a normal recurring nature necessary for presentation of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with the instructions to Form 10-Q in Article 10 of SEC Regulation S-X. As used in this report, the term the “Company” means Bakhu Holdings, Corp. and its subsidiary, unless the context indicates otherwise.

The Company condensed or omitted certain information and footnote disclosures normally included in our annual audited financial statements, which the Company prepared in accordance with GAAP. Our interim financial statements should be read in conjunction with our annual report on Form 10-K for the year ended July 31, 2023.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Going Concern

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of $4849,~~731~~638,~~646~~483 as of ~~January~~April 3130, 2024 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

Page 9

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation

The Company’s functional currency and its reporting currency is the United States dollar.

Financial Instruments

The carrying value of the Company’s financial instruments approximates their fair value because of the short maturity of these instruments.

Stock-based Compensation

In September 2020, the Company adopted a stock-based compensation plan, the 2020 Long-Term Incentive Plan (“2020 Plan”), which is more fully described in Note 5. We expense the fair value of stock options and warrants granted for services as they vest. The fair value of each option grant issued under the 2020 Plan is calculated using the Black-Scholes option pricing model.

The Company recognized stock-based compensation of $~~797~~1,~~968~~256,951 and $57,~~640~~353,~~211~~885 (which is included in consulting fees on the ~~Statement~~Statements of Operations) for the ~~six~~nine months ended ~~January~~April 3130, 2024 and 2023, respectively. As of ~~January~~April 3130, 2024, there was $3,~~191~~092,~~873~~886 of total unrecognized stock-based compensation that is expected to be recognized over the remaining vesting period of the options (which ends on February 11, 2026).

Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

Basic and Diluted Net Loss per Share

The Company computes net loss per share in accordance with ASC 105, “Earnings per Share.” ASC 105 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement.

Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all potentially dilutive common shares outstanding (such as stock options, warrants, and convertible notes payable) during the period. Diluted EPS excludes all potentially dilutive shares if their effect is anti-dilutive.

Professional fees

Substantially all professional fees presented in the financial statements represent accounting fees, audit fees and legal fees associated with the filing of reports with the Securities and Exchange Commission. Also included in professional fees are fees paid to the stock transfer agent. The fees are expensed as incurred.

Page 10

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Fiscal Periods

The Company’s fiscal year end is July 31.

Recently Issued Accounting Pronouncements

The Company has reviewed accounting pronouncements issued during the past two years and have adopted any that are applicable to the Company. We have determined that none had a material impact on our financial position, results of operations, or cash flows for the periods presented in this report.

NOTE 3 – FIXED ASSETS

On January 31, 2022, the Company and Cell Science entered into the Third Amendment to the December 20, 2018 Patent and Technology License Agreement (see Note 7). As part of this transaction, the Company acquired all related equipment, improvements, supplies, and related tangible and intangible assets. The Company determined that the lab equipment acquired had a cost basis of $765,160. These costs are depreciated using the straight-line method over their estimated economic lives which is estimated to be 5 years.

Fixed Assets consisted of the following:

	January 31, 2024	July 31, 2023
	April 30, 2024	July 31, 2023
Laboratory equipment and components – at cost	$668,358	$668,357
Accumulated depreciation	(~~267~~300,~~343~~761)	(200,507)
Fixed assets – net	$~~401~~367,~~015~~597	$467,850

NOTE 4 - NOTES PAYABLE

Notes payable – related parties consist of:

	January 31, 2024	July 31, 2023
	April 30, 2024	July 31, 2023
Note payable to Cell Science Holding Ltd. dated January 31, 2022, interest at 0.44%, due December 31, 2027	$3,~~420~~330,000	$3,500,000
Convertible note payable to The OZ Corporation dated August 1, 2019, interest at 6%, due December 31, 2027	3,~~183~~283,~~972~~472	3,094,672
Note payable to The OZ Corporation dated June 23, 2022, interest at 7%, due December 15, 2024	150,000	150,000
Convertible Senior Secured Promissory Note payable to OZ Company, interest at 13%, due February 27, 2028	500,000	-
Convertible Senior Secured Promissory Note payable to OZ Company, interest at 13%, due February 26, 2028	546,574	-
Total notes payable – related parties	7,~~253~~310,~~972~~046	6,744,672
Current portion of notes payable – related parties	(150,000)	(6,744,672)
Non-current portion of notes payable – related parties	$7,~~103~~160,~~972~~046	$-

Notes payable – third parties consist of:

	January 31, 2024	July 31, 2023
	April 30, 2024	July 31, 2023
Convertible Senior Secured Promissory Notes payable to third parties, interest at 13%, due February 27, 2028	$530,000	$-
Convertible Senior Secured Promissory Notes payable to third parties, interest at 13%, due February 26, 2028	$653,770	$-
Total notes payable – third parties	$~~530~~653,~~000~~770	$-

Page 11

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 4 - NOTES PAYABLE (continued)

On January 31, 2022, the Company and Cell Science entered into the Third Amendment to the December 20, 2018 Patent and Technology License Agreement (see Note 7). As part of this transaction, the Company issued a $3,500,000 promissory note, bearing interest at the applicable federal short-term rate of 0.44% under IRC Section 1274(d), originally due in January 2023 which by successive amendments has been extended to December 31, 2027. The principal balance and accrued interest due on the note were $3,~~420~~330,000 and $3034,~~800~~510, respectively, as of ~~January~~April 3130, 2024.

The Convertible note payable to The OZ Corporation dated August 1, 2019 arose from a promissory note in favor of The OZ Corporation to evidence monies loaned to the Company from December 26, 2018 through July 31, 2019 in the amount of $147,513, and to evidence any additional amounts that may be loaned to the Company thereafter. Pursuant to the terms of the promissory note, the principal and unpaid accrued simple interest at the rate of 6.0% per annum was due and payable on or before December 31, 2019 which by successive amendments the due date was extended to December 31, 2027. The principal amount of the promissory note has been increased by the amount of any additional advances of funds made by The OZ Corporation to the Company, from time to time, from the date of such advance. Under the terms of the promissory note, The OZ Corporation, at its option may, at any time, convert all or any portion of the then unpaid principal balance and any unpaid accrued interest into shares of the Company’s common stock. The number of shares of common stock to be issued upon such conversion shall be equal to the quotient obtained by dividing (i) the then unpaid principal balance and any unpaid accrued interest of the promissory note being converted by (ii) 80% of the average closing price of the common stock of the Company, for the ninety (90) trading days before the conversion date, rounded up to the nearest whole share. The principal balance and accrued interest due on the note were $3,~~183~~283,~~972~~472 and $~~466~~511,~~823~~378, respectively, as of ~~January~~April 3130, 2024.

On June 23, 2022, the Company executed a promissory note in favor of The OZ Corporation, in the amount of $150,000. Pursuant to the terms of the promissory note, the principal and unpaid accrued simple interest at the rate of 7.0% per annum shall be due and payable on or before December 15, 2024. The principal balance and accrued interest due on the note were $150,000 and $1619,~~883~~475, respectively, as of ~~January~~April 3130, 2024.

The Convertible Senior Secured Promissory Notes payable to OZ Company (related party) and ~~three~~six third parties at ~~January~~April 3130, 2024 were sold by the Company from August 8, 2023 to ~~January~~February 1029, 2024. These notes accrue interest at the rate of 13% per annum which is compounded quarterly with the compounded quarterly interest being added to the outstanding principal balance of the note on the last day of each fiscal quarter of the Company. The principal and related accrued interest are convertible at the option of the holder into shares of Company common stock at a conversion price of $0.50 per share. These notes are secured by a first priority lien on all assets of the Company. The principal balance and accrued interest due on the Convertible Senior Secured Promissory Notes totaled $1,~~030~~200,~~000~~344 and $380,~~946,~~ respectively as of ~~January~~April 3130, 2024.

Upon conversion of the notes, the Company will issue one warrant for each dollar amount converted, with an exercise price of $0.50 per share for warrants issued on conversion of the first $1.5 million of 13% Convertible Secured Notes issued, an exercise price of $0.75 per share for warrants issued on conversion of the second $3.5 million tranche of 13% Convertible Secured Notes issued and an exercise price of $1.00 per share for warrants issued on conversion of 13% Convertible Secured Notes issued after the first $5.0 million in notes issued.

The total note proceeds of $1,030,000 were deposited in a third-party escrow account. From August 29, 2023 to January 31, 2024, a total of $607,500 was disbursed from escrow to pay accounts payable and current operating expenses. The balance in the escrow account at January 31, 2024 was $422,500. From February 1, 2024 to February 26, 2024, a total of $345,976 was disbursed from escrow to pay accounts payable and current operating expenses. On February 26, 2024, the remaining $76,524 in escrow was transferred to the Company’s bank account.

NOTE 5 - PREFERRED AND COMMON STOCK

Preferred Stock

In connection with the December 20, 2018 Patent and Technology Agreement, the Company issued 4 shares of its Series A Preferred Stock to Cell Science. Each share of Series A Preferred Stock had voting rights equal to four (4) times the aggregate votes of the total number of shares of common stock issued and outstanding plus the total number of votes of all other classes of preferred stock issued and outstanding, divided by the number of shares of Series A Preferred Stock issued and outstanding. On September 18, 2023, Cell Science agreed to cancel the four outstanding shares of Series A Preferred Stock owned by it. As a result of this preferred stock cancellation, Cell Science no longer has the voting power to control all stockholder votes, and we are amending our certificates of

Page 12

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 5 - PREFERRED AND COMMON STOCK (continued)

Series A Preferred Stock issued and outstanding. On September 18, 2023, Cell Science agreed to cancel the four outstanding shares of Series A Preferred Stock owned by it. As a result of this preferred stock cancellation, Cell Science no longer has the voting power to control all stockholder votes, and we are amending our certificates of designation so that the Series A Preferred Stock and Series B Preferred Stock are no longer authorized for future issuance. We now have outstanding only common stock, which is entitled to one vote per share on all matters.

Stock Option Plan

On September 22, 2020, the board of directors adopted the 2020 Long-Term Incentive Plan (“2020 Plan”), under which 20,000,000 shares of our common stock were reserved for issuance by us to attract and retain employees and directors and to provide such persons with incentives and awards for superior performance and providing services to us. The 2020 Plan is administered by a committee comprised of our board of directors or appointed by the board of directors, which has broad flexibility in designing stock-based incentives. The board of directors determines the number of shares granted and the option exercise price pursuant to the 2020 Plan.

~~The~~On ~~following~~February ~~table~~27, ~~summarizes~~2024, the Company closed Tranche 1 of the ongoing private placement sale of $1,030,000 of Convertible Senior Secured Promissory Notes (see Note 4). In conjunction with the Tranche 1 closing, the Company appointed three new directors and granted to each of the new directors Teddy Scott, Mitch Kahn, and Kimberly Tanami, and incumbent directors, Aristotle Popolizio, Peter Whitton and Juan Carlos Garcia La Sienra Garcia, a non-qualified stock option ~~award~~to ~~activity~~purchase ~~under~~240,000 ~~the~~shares ~~2020~~of ~~Plan~~common ~~during~~stock at an exercise price of $1.00 per share. Such options shall be exercisable for seven years. The options shall vest at the ~~six~~rate ~~months~~of ~~ended~~1/12 ~~January~~(i.e., 3120,000 ~~2024:~~shares) per month commencing on the Grant Date, so that all options shall be fully vested and exercisable on the first anniversary of the Grant Date.

		Number of options
Outstanding at July 31, 2023		10,943,075
Granted		-
Exercised		-
Forfeited		(240,000)
Expired		-
Outstanding at January 31, 2024		10,703,075

Unless a director resigns, is removed as provided in the Bylaws of the Company, dies or becomes incapacitated, each director shall receive annually, on each anniversary date, an additional option to purchase 240,000 shares of the Company’s common stock at an exercise price per share equal to the greater of (i) $1.00 per share, or (ii) Market price, defined as the average of the reported closing transaction price, if available, or closing bid price VWAP for the seven trading days preceding the date of grant, unless the aggregate trading volume for such period was less than $100,000, in which case the applicable trading period will be that number of days required to have aggregate trading volume of $100,000. Such annual grant of options shall continue in effect until the director resigns, is removed as provided in the Bylaws of the Company, dies or becomes incapacitated.

On March 5, 2024, John Munoz (controlling person of The ~~following~~OZ ~~table~~Corporation ~~summarizes~~and ~~the~~OZ ~~warrants~~Company) ~~activity~~and ~~during~~Aristotle Popolizio (officer and director of the ~~six~~Company) ~~months~~closed ~~ended~~an ~~January~~Option 31Cancellation and Share Transfer Agreement. In exchange for Popolizio’s cancellation of a total of 2,100,000 ~~2024:~~stock options exercisable at prices ranging from $2.60 per share to $5.10 per share, Munoz transferred 2,500,000 shares of Company common stock owned by him to Popolizio.

		Number of Warrants
Outstanding at July 31, 2023		750,000
Granted		-
Exercised		-
Expired		-
Outstanding at January 31, 2024		750,000

The following table summarizes the stock option award activity under the 2020 Plan during the nine months ended April 30, 2024:

The remaining 10,703,075 stock options outstanding at January 31, 2024 are as follows:

		Number of options
Outstanding at July 31, 2023		10,943,075
Granted		1,440,000
Exercised		-
Forfeited		(2,340,000)
Expired		(360,000)
Outstanding at April 30, 2024		9,683,075

Date of Grant	Number Outstanding	Number Exercisable	Exercise Price	Expiration Date
September 22, 2020	300,000	300,000	$5.10	September 22, 2027
July 27, 2021	200,000	200,000	$4.20	July 27, 2028
September 16, 2021	718,085	718,085	$4.50	September 16, 2031
December 3, 2021	140,000	140,000	$3.00	December 3, 2028
December 6, 2021	140,000	140,000	$3.40	December 6, 2021
December 7, 2021	400,000	400,000	$3.40	December 7, 2028
January 5, 2022	1,400,000	1,400,000	$2.60	January 5, 2029
February 11, 2022	624,990	624,990	$3.00	February 11, 2029
February 11, 2022	3,500,000	1,499,984	$3.00	February 11, 2029
April 18, 2022	2,600,000	2,600,000	$3.30	April 18, 2029
July 29, 2022	360,000	360,000	$1.50	July 29, 2029
July 29, 2022	320,000	320,000	$1.50	July 29, 2029
Totals	10,703,075	8,703,059

The remaining 750,000 warrants outstanding and exercisable at January 31, 2024 were granted September 11, 2021, have an exercise price of $3.00 per share, and expire June 7, 2028.

Page 13

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 5 - PREFERRED AND COMMON STOCK (continued)

The following table summarizes the warrants activity during the nine months ended April 30, 2024:

		Number of Warrants
Outstanding at July 31, 2023		750,000
Granted		-
Exercised		-
Expired		-
Outstanding at April 30, 2024		750,000

The remaining 9,683,075 stock options outstanding at April 30, 2024 are as follows:

Date of Grant	Number Outstanding	Number Exercisable	Exercise Price	Expiration Date
September 22, 2020	200,000	200,000	$5.10	September 22, 2027
July 27, 2021	200,000	200,000	$4.20	July 27, 2028
September 16, 2021	718,085	718,085	$4.50	September 16, 2031
December 3, 2021	140,000	140,000	$3.00	December 3, 2028
December 6, 2021	140,000	140,000	$3.40	December 6, 2028
December 7, 2021	400,000	400,000	$3.40	December 7, 2028
January 5, 2022	700,000	700,000	$2.60	January 5, 2029
February 11, 2022	624,990	624,990	$3.00	February 11, 2029
February 11, 2022	3,500,000	1,624,982	$3.00	February 11, 2029
April 18, 2022	1,300,000	1,300,000	$3.30	April 18, 2029
July 29, 2022	320,000	320,000	$1.50	July 29, 2029
February 27, 2024	1,440,000	240,000	$1.00	February 28, 2031
Totals	9,683,075	6,608,057

The remaining 750,000 warrants outstanding and exercisable at April 30, 2024 were granted September 11, 2021, have an exercise price of $3.00 per share, and expire June 7, 2028.

NOTE 6 - INCOME TAXES

As of ~~January~~April 3130, 2024, the Company had net operating loss carry forwards that may be available to reduce future years’ taxable income. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not more likely than not to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

NOTE 7 - COMMITMENTS AND CONTINGENCIES

Office Cost Sharing Agreement

On September 22, 2020, the Company executed an Office Cost Sharing Agreement with The OZ Corporation. The agreement provides for the Company’s payments to The OZ Corporation of $34,000 per month for the shared use of office space located in Long Beach California for so long as The OZ Corporation provides the Company with shared use of the premises. For the ~~six~~nine months ended ~~January~~April 3130, 2024 and 2023, the space sharing fees were $~~204~~306,000 and $~~204~~306,000, respectively. As of ~~January~~April 3130, 2024, accounts payable and accrued liabilities included $1,~~205~~307,000 due to The OZ Corporation for unpaid space sharing fees.

Patent and Technology license Agreements

Under the April 2020 strategic alliance agreement and related sublicense between the Company’s subsidiary, CBD Biotech, Inc., and Integrity Cannabis Solutions, Inc. (“ICS”), the Company is obligated to issue to ICS that number of shares of Bakhu common stock equal to 0.5% of the number of shares outstanding as of the date that the production facility of ICS is completed and commences production. Further, if the sublicense is terminated, CBD Biotech will be obligated to repay to ICS its initial $250,000 license fee and reimburse ICS for the cost of the laboratory operational equipment used in its production facility, which thereafter will be owned and managed jointly by ICS and CBD Biotech.

As a result of successfully completing the efficacy demonstration of our licensed technology in July 2021, we became obligated to issue to Cell Science, the licensor, a one-year note for an agreed one-time payment of $3.5 million, less certain credits. The amount of the credits to the note were determined and on January 31, 2022, the Company and Cell Science entered into the Third Amendment to the December 20, 2018 Patent and Technology License Agreement, as subsequently amended, in which the Company and Cell Science agreed as follows:

·There would be no reduction or offset against the $3.5 million One-time Payment for costs paid by the Company or on its behalf. Therefore, the Company issued a $3.5 million promissory note, bearing interest at the applicable federal short-term rate of 0.44% under IRC Section 1274(d), originally payable on January 31, 2023, as extended by successive amendments to December 31, 2027.

·In lieu of any offset or reduction against the One-Time Payment Note, Cell Science agreed to convey to the Company the lease on the California laboratory in which the efficacy demonstration was conducted, including all related equipment, improvements, supplies, and related tangible and intangible assets.

·Cell Science and The OZ Corporation would execute and deliver to the Company a similar conveyance of all rights to the California laboratory.

·The Integrated License Agreement was clarified to provide that all improvements to the licensed technology made by the Company would be owned by Cell Science and included in the license.

Page 14

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 7 - COMMITMENTS AND CONTINGENCIES (continued)

~~lessee’s~~production ~~operations. From~~facility ~~March~~of ~~12,~~ICS ~~2023~~is ~~through~~completed ~~August~~and ~~2023~~commences production. Further, if the ~~agreement~~sublicense ~~continued~~is onterminated, aCBD ~~month-to-month~~Biotech ~~basis. For~~will ~~the~~be ~~six~~obligated ~~months~~to ~~ended~~repay ~~January~~to 31ICS its initial $250,000 ~~2024~~license fee and ~~2023,~~reimburse ICS for the ~~space~~cost ~~sharing~~of ~~fees~~the ~~were~~laboratory ~~$10,000~~operational ~~and~~equipment ~~$60,000,~~used ~~respectively~~in its production facility, ~~and~~which ~~the~~thereafter ~~cannabis~~will ~~activities~~be ~~fees~~owned ~~were~~and ~~$11,640~~managed jointly by ICS and ~~$69,840,~~CBD ~~respectively~~Biotech.

·Cell Science and The OZ Corporation would execute and deliver to the Company a similar conveyance of all rights to the California laboratory.

·The Integrated License Agreement was clarified to provide that all improvements to the licensed technology made by the Company would be owned by Cell Science and included in the license.

The lease on the California laboratory space located in Sherman Oaks, California, as amended March 12, 2020 and assumed by the Company on January 31, 2022, provided for a monthly space sharing fee of $10,000 and had a term of thirty six (36) months from March 12, 2020 to March 12, 2023 with an option to extend for an additional period not to exceed three (3) months. In addition, the agreement provided for a monthly cannabis activities fee equal to the greater of (i) $11,640 or (ii) ten percent (10%) of the gross sales of the products, if any, manufactured through lessee’s operations. From March 12, 2023 through August 2023, the agreement continued on a month-to-month basis. For the nine months ended April 30, 2024 and 2023, the space sharing fees were $10,000 and $90,000, respectively, and the cannabis activities fees were $11,640 and $104,760, respectively.

NOTE 8 – GAIN ON SETTLEMENT OF DEBT

On December 7, 2023, we reached an agreement with VO Leasing Corp., our laboratory space landlord and holder of necessary cannabis cultivation and manufacturing licenses in CA, in settlement of the $623,078 owed VO Leasing as of October 31, 2023. Per the agreement, it was agreed that we would pay VO Leasing the total amount of $300,000 with interest thereon at the rate of 10% per annum as full satisfaction of the amounts owed. Under the agreement, we paid $40,000. The balance of $260,000 plus all accrued and unpaid interest is payable within 180 days (the “Due Date”). With the payment of the initial $40,000 we were permitted to retrieve the Bioreactors from the premises. Additionally, per the agreement, upon our payment, ~~anytime~~any time before the Due Date, of an additional $50,000 applied against the balance due, we can retrieve all of our remaining equipment, except the Filtration System, which shall be Collateral for our full performance under the agreement, and which shall be released upon full payment prior to the Due Date. Based on the agreement, the Company recorded a gain on the settlement of debt in the amount of $323,078 ~~for~~in the three ~~and six~~ months ended January 31, 2024. As of the date of issuance of the accompanying financial statements, the Company has not paid any of the $260,000 balance and accrued interest due VO Leasing Corp.

NOTE 9 – RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company has restated the consolidated Financial Statements for the three and six months ended January 31, 2023 (which were included in the Company’s Form 10-Q filed with the SEC on December 20, 2022) in order to correct the consulting fees expense related to warrants issued. The Company had previously expensed warrants that had not yet vested and therefore had overstated consulting fees expense.

The effect of the restatement adjustment on the Consolidated Statement of Operations for the three months ended January 31, 2023 follows:

	As previously Reported	Restatement Adjustment	As Restated
Revenues	$-	$-	$-
Operating expenses:
Consulting fees	4,006,725	(1,361,913)	2,644,812
Professional fees	178,495	-	178,495
Depreciation of fixed assets	33,418	-	33,418
Other operating expenses	233,408	-	233,408
Total operating expenses	4,452,046	(1,361,913)	3,090,133
Loss from operations	(4,452,046)	1,361,913	(3,090,133)
Other expenses	(48,830)	-	(48,830)
Net Loss	$(4,500,876)	$1,361,913	$(3,138,963)
Net loss per share – basic and diluted	$(0.01)	$0.00	$(0.01)

Page 15

BAKHU HOLDINGS, CORP.

Notes to Consolidated Financial Statements

~~January~~April 3130, 2024

(Unaudited)

NOTE 9 – RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS ~~(continued)~~

The ~~effect~~Company ofhas restated the ~~restatement~~consolidated ~~adjustment~~Financial onStatements for the ~~Consolidated~~three ~~Statement~~and ofnine ~~Operations~~months ~~for~~ended April 30, 2023 (which were included in the ~~six~~Company’s ~~months~~Form ~~ended~~10-Q ~~January~~filed 31with the SEC on December 20, ~~2023~~2022) ~~follows:~~in order to correct the consulting fees expense related to warrants issued. The Company had previously expensed warrants that had not yet vested and therefore had overstated consulting fees expense.

	As previously Reported	Restatement Adjustment	As Restated
Revenues	$-	$-	$-
Operating expenses:
Consulting fees	8,534,725	(2,723,826)	5,810,899
Professional fees	348,718	-	348,718
Depreciation of fixed assets	66,836	-	66,836
Other operating expenses	523,922	-	523,922
Total operating expenses	9,474,201	(2,723,826)	6,750,375
Loss from operations	(9,474,201)	2,723,826	(6,750,375
Other expenses	(161,241)	-	(161,241)
Net Loss	$(9,635,442)	$2,723,826	$(6,911,616)
Net loss per share – basic and diluted	$(0.03)	$0.01	$(0.02)

The effect of the restatement adjustment on the Consolidated Statement of Operations for the three months ended April 30, 2023 follows:

NOTE 10 – SUBSEQUENT EVENTS

	As previously Reported	Restatement Adjustment	As Restated

Revenues	$-	$-	$-

Operating expenses:
Consulting fees	3,141,583	(1,361,913)	1,779,670
Professional fees	52,008	-	52,008
Depreciation of fixed assets	33,418	-	33,418
Other operating expenses	229,700	-	229,700
Total operating expenses	3,456,709	(1,361,913)	2,094,796
Loss from operations	(3,456,709)	1,361,913	(2,094,796)
Other expenses	(48,037)	-	(48,037)
Net Loss	$(3,504,746)	$1,361,913	$(2,142,833)
Net loss per share – basic and diluted	$(0.01)	$0.00	$(0.01)

OnThe ~~February~~effect ~~27, 2024, the Company closed Tranche 1~~ of the ~~ongoing~~restatement ~~private~~adjustment ~~placement~~on ~~sale of $1,030,000 of Convertible Senior Secured Promissory Notes (see Note 4). In conjunction with~~ the ~~Tranche~~Consolidated 1Statement ~~closing, the Company appointed three new directors and granted to each~~ of ~~the~~Operations new directors Teddy Scott, Mitch Kahn, and Kimberly Tanami, and incumbent directors, Aristotle Popolizio, Peter Whitton and Juan Carlos Garcia La Sienra Garcia, a non-qualified stock option to purchase 240,000 shares of common stock at an exercise price of $1.00 per share. Such options shall be exercisable for ~~seven years. The options shall vest at~~ the ~~rate~~nine ofmonths ~~1/12~~ended ~~(i.e.,~~April 2030,~~000~~ ~~shares)~~2023 ~~per month commencing on the Grant Date, so that all options shall be fully vested and exercisable on the first anniversary of the Grant Date.~~ follows:

	As previously Reported	Restatement Adjustment	As Restated

Revenues	$-	$-	$-

Operating expenses:
Consulting fees	11,676,308	(4,085,739)	7,590,569
Professional fees	400,726	-	400,726
Depreciation of fixed assets	100,254	-	100,254
Other operating expenses	753,622	-	753,622
Total operating expenses	12,930,910	(4,085,739)	8,845,171
Loss from operations	(12,930,910)	4,085,739	(8,845,171)
Other expenses	(209,278)	-	(209,278)
Net Loss	$(13,140,188)	$4,085,739	$(9,054,449)
Net loss per share – basic and diluted	$(0.04)	$0.01	$(0.03)

On March 5, 2024, John Munoz (controlling person of The OZ Corporation and OZ Company) and Aristotle Popolizio (officer and director of the Company) closed an Option Cancellation and Share Transfer Agreement. In exchange for Popolizio’s cancellation of a total of 2,100,000 stock options exercisable at prices ranging from $2.60 per share to $5.10 per share, Munoz transferred 2,500,000 shares of Company common stock owned by him to Popolizio.

Page 16

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act relating to future events or our future performance. The following discussion should be read in conjunction with our consolidated financial statements and notes to our financial statements included elsewhere in this report. This discussion contains forward-looking statements that relate to future events or our future performance. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, we cannot assure that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

Business Overview

Since December 2018, we have focused on testing and commercializing cannabis plant cell-extraction and replication technologies under a technology license granted by Cell Science. This licensed technology uses plant cell-extraction and replication technology and related proprietary equipment, processes, and medium formulations in a commercially-sized bioreactor laboratory to produce, manufacture, and sell plant-based cannabis products —sometimes referred in the industry as cannabinoids—exclusively in North and Central America and the Caribbean for medical, food additive, and recreational uses.

During our fiscal quarter ended January 31, 2022, we undertook additional work to determine the limits of the technology, maximize production efficiency, and reduce production costs, which we believe will enhance our commercialization efforts. Subject to successfully completing our ongoing work, we intend to seek to commercialize the licensed technology through joint ventures, strategic partners, sublicenses, and other arrangements that may enable us to take advantage of the technical experience, regulatory relationships, and financial resources of experienced cannabinoid production firms. We intend to authorize these third parties to incorporate the technology into production facilities they fund, build, and operate to produce medical, food additive, and recreational cannabis-related products in compliance with applicable state and federal law. We will need additional financing from external sources to begin these commercialization efforts.

During the last three fiscal years and the recently completed three- and six-month periods, we have not generated revenue and have devoted our limited management, technical, and financial resources to pay general and administrative expenses to position us to be able to commercially exploit the licensed technology. In July 2021, we completed efficacy testing of our licensed technology required to demonstrate its commercial viability. As we seek to implement our commercialization plan, we are seeking substantial amounts of required additional capital.

~~Results~~Financial ofCondition—Our ~~Operations~~Insolvency

~~Following~~As isshown ~~management’s~~by ~~discussion~~the financial statements included in this report and as discussed below, we are unable to pay our liabilities as they become due and are, therefore, insolvent under a cash flow analysis. Accordingly, creditors may be able to initiate judicially supervised reorganization or liquidation proceedings against us under the Bankruptcy Act or similar state statutes. If such proceedings were initiated, the court having jurisdiction would take control of our affairs and the ~~relevant~~resolution ~~items~~of ~~affecting~~the ~~results~~rights of ~~operations~~creditors and others having a claim or interest in us. In such circumstances, the claims of secured creditors, which have a lien on all of our assets, and other creditors would have rights senior to the rights of shareholders, who may recover no value for their investment. We would lose control of our affairs and the ~~three~~resolution of the claims and ~~six~~interests ~~months~~of ~~ended~~our ~~January~~creditors, 31stockholders, ~~2024~~intellectual property licensor, and ~~2023~~others.

~~Revenues.~~As Weof ~~generated~~April no30, ~~net~~2024, ~~revenues~~our ~~during~~aggregate ~~the~~liabilities ~~three~~were ~~and~~$10,747,336, ~~six~~including ~~months~~$2,933,520 ~~ended~~in ~~January~~current 31liabilities, ~~2024~~as ~~and~~compared ~~2023~~to total assets of $470,951, including $3,101 in current assets, for a working capital deficit of $2,930,329. We doAlmost ~~not~~all ~~expect~~of toour ~~generate~~current ~~revenues~~liabilities ~~until~~were weover ~~launch~~30 days past due. A substantial portion of our ~~proposed~~current ~~commercialization~~liabilities ~~program~~has been past due for over 18 months. WeAs ~~cannot~~we ~~predict~~continue ~~whether~~efforts to seek external funding, we intend to seek to negotiate extended or ~~when~~discounted ~~that~~payments for many of these creditors but may ~~occur~~be unable to do so. Such creditors may have the power to initiate insolvency proceedings against us. Further, the requirement that we use net proceeds from new financings to pay delinquent obligations, particularly to related parties, will negatively impact our fundraising.

Consulting Fees. Consulting fees were $171,254 and $2,644,812 for the three months ended January 31, 2024, and 2023, respectively. Consulting fees were $863,860 and $5,810,899 for the six months ended January 31, 2024, and 2023, respectively. We recognized stock-based compensation of $797,968 and $5,640,211 for the six months ended January 31, 2024 and 2023, respectively, attributable to the issuance of options and warrants. See Stock-based Compensation under Note 2 in the Notes to Financial Statements for description of options and warrants granted.

Professional Fees. Professional fees were $2,472 and $178,495 for the three months ended January 31, 2024 and 2023, respectively. Professional fees were $194,798 and $348,718 for the six months ended January 31, 2024 and 2023, respectively. Professional fees consist of legal and accounting fees associated with our reporting obligations under federal securities laws and the filing of a registration statement on behalf of stockholders for the resale of outstanding securities.

Page 17

~~Other~~Results ~~Operating~~of Expenses. Other operating expenses were $160,086 and $233,408 for the three months ended January 31, 2024, and 2023, respectively. Other operating expenses were $309,103 and $523,922 for the six months ended January 31, 2024, and 2023, respectively. SG&A expenses include laboratory expenses, including office facility charges, insurance, equipment, staff and other related laboratory costs, which we expect will continue. Operations

~~Other~~Following ~~Income~~is ~~(Expenses). We~~management’s ~~had~~discussion ~~net other income~~ of ~~$246,550 for~~ the ~~three~~relevant ~~months~~items ~~ended~~affecting ~~January~~results ~~31, 2024 compared to net other expenses~~ of ~~$48,830~~operations for the three months ended January 31, 2023. We had net other income of $182,439 for the six months ended January 31, 2024 compared to net other expenses of $161,241 for the six months ended January 31, 2023. During the three and ~~six~~nine months ended ~~January~~April 3130, 2024, we recorded a gain on the settlement of debt in the amount of $323,078. See Gain on Settlement of Debt under Note 10 in the Notes to Financial Statements for description of the gain. Included in other expenses for the six months ended January 31, 2023, was the loss on sale of equipment in the amount of $65,748. Also included in other expenses were interest expenses related to our notes payable to related parties in the amount of $140,639 and ~~$95,493 for the six months ended January 31, 2024 and~~ 2023~~, respectively~~. ~~The increase in interest expenses is a result of the increase in loans and notes payable due to related parties. These borrowed funds were used for operating expenses.~~

~~Net Loss~~Revenues. We ~~had~~generated ano ~~net~~revenues ~~loss~~during ~~of $120,680 and $3,138,963 for~~ the three ~~months ended January 31, 2024,~~ and ~~2023,~~nine ~~respectively. We had a net loss of $1,252,158 and $6,911,616 for the six~~ months ended ~~January~~April 3130, 2024, and 2023~~, respectively~~. ~~Other~~We ~~than~~do ~~the decrease in stock-based compensation, we did~~ not expect ato ~~major~~generate ~~change~~revenues inuntil ~~our~~we ~~net~~launch ~~loss~~our asproposed ~~our~~commercialization ~~operations~~program. ~~remain~~We ~~relatively~~cannot ~~the~~predict ~~same~~whether asor ~~the~~when ~~prior~~that ~~year~~may occur.

Consulting Fees. Consulting fees were $468,484 and $1,779,670 for the three months ended April 30, 2024, and 2023, respectively. Consulting fees were $1,332,344 and $7,590,569 for the nine months ended April 30, 2024, and 2023, respectively. The reductions in the subsequent periods reflect few options and warrants issued in the later periods as our compensation of officers, directors, and consultants declined, reflecting limitations of activities due to shortages of funding. We recognized stock-based compensation of $1,256,951 and $7,353,885 for the nine months ended April 30, 2024 and 2023, respectively, attributable to the issuance of options and warrants. See Stock-based Compensation under Note 2 in the Notes to Financial Statements for description of options and warrants granted.

Professional Fees. Professional fees were $87,675 and $52,008 for the three months ended April 30, 2024 and 2023, respectively. Professional fees were $282,473 and $400,726 for the nine months ended April 30, 2024 and 2023, respectively. Professional fees consist of legal and accounting fees associated with our reporting obligations under federal securities laws and the filing of a registration statement on behalf of stockholders for the resale of outstanding securities.

Other Operating Expenses. Other operating expenses were $228,344 and $229,700 for the three months ended April 30, 2024, and 2023, respectively. Other operating expenses were $537,446 and $753,622 for the nine months ended April 30, 2024, and 2023, respectively. SG&A expenses include laboratory expenses, including office facility charges, insurance, equipment, staff and other related laboratory costs, which we expect will continue which generally declines as activities were reduced in the later periods due to funding shortages.

Other Income (Expenses). We had net other expenses of $88,916 and $48,037 for the three months ended April 30, 2024 and 2023, respectively. We had net other income of $93,523 for the nine months ended April 30, 2024 compared to net other expenses of $209,278 for the nine months ended April 30, 2023. During the nine months ended April 30, 2024, we recorded a gain on the settlement of debt in the amount of $323,078. See Gain on Settlement of Debt under Note 10 in the Notes to Financial Statements for description of the gain. Included in other expenses for the nine months ended April 30, 2023, was the loss on sale of equipment in the amount of $65,748. Also included in other expenses were interest expenses related to our notes payable in the amount of $229,555 and $143,530 for the nine months ended April 30, 2024 and 2023, respectively. The increase in interest expenses is a result of the increase in loans and notes payable. These borrowed funds were used for operating expenses.

Net Loss. We had a net loss of $906,837 and $2,142,833 for the three months ended April 30, 2024, and 2023, respectively. We had a net loss of $2,158,995 and $9,054,449 for the nine months ended April 30, 2024, and 2023, respectively. Other than the decrease in stock-based compensation, we did not expect a major change in our net loss as our operations remain relatively the same as the prior year.

Liquidity and Capital Resources

As of ~~January~~April 3130, 2024, our primary source of liquidity consisted of $~~426~~81,~~347~~519 in cash and cash equivalents. Since inception, we have financed our operations through a combination of short and long-term loans ~~from related parties~~ and through the private placement of our common stock.

For the ~~six~~nine months ended ~~January~~April 3130, 2024, cash increased $~~423~~78,~~246~~418 from $3,101 at July 31, 2023, to $~~426~~81,~~347~~519 at ~~January~~April 3130, 2024.

Net cash used in operating activities was $~~616~~1,~~054~~065,382 during the ~~six~~nine months ended ~~January~~April 3130, 2024, with a net loss of $12,~~252,~~158,995, stock-based compensation of $~~797~~1,~~968~~256,951, gain on settlement of debt of $323,078, depreciation expense of $68100,~~835~~253, an increase in prepaid expenses of $70,361, a decrease in accounts payable of $~~692~~358,~~416~~046, ~~and~~ an increase in accrued liabilities of $~~140~~227,~~639~~894, and the settlement liability of $260,000.

~~Net~~Page ~~cash provided by investing activities was $-0- during the six months ended January 31, 2024.~~ 18

~~During~~Net ~~the~~cash ~~six~~provided ~~months~~by ~~ended~~investing ~~January 31, 2024, financing~~ activities ~~provided~~was $~~1,039,300~~-0- induring ~~net~~the ~~cash~~nine ~~which~~months ~~consisted~~ended ofApril ~~proceeds from notes payable of $530~~30,~~000~~ ~~and proceeds from notes payable – related parties in the amount of $509,300~~2024.

During the nine months ended April 30, 2024, financing activities provided $1,143,800 in net cash which consisted of proceeds from notes payable of $625,000 and proceeds from notes payable – related parties in the amount of $518,800.

Future Capital Requirements

Our ability to continue as a going concern is contingent upon our ability to obtain capital through the sale of equity or issuance of debt, and ultimately attaining profitable operations. We expect that any financing we receive will be similar to what we have heretofore received over the previous two years to enable us to operate, which financing consists of short-term loans from related parties at negotiated rates of interest. We cannot assure you that we will be able to successfully complete any of these activities.

We ~~estimate~~previously estimated that we ~~will~~would require a minimum of approximately $8.5 million in external capital to continue and to fund our activities during the next 12 months. Our recently expanded board of directors is now reviewing our business plan and estimated funding requirements and expect that this estimate may be revised. Any additional funds available would be used for planned laboratory work to improve and customize our licensed processes and commercialize our technology. The actual amount of work completed will depend on the amount of capital available for those expenditures. Reductions in available capital would correspondingly delay and disrupt laboratory plans and, in turn, the commencement of our commercialization program that we anticipate will lead to recurring revenue. Less available capital will require us to implement cost-cutting measures and may delay planned activities.

Page 18

We are currently seeking an additional between $9.0 and $19.0 million through the sale of convertible secured notes to reduce our liabilities and to fund our proposed activities. As we continue our efforts to reach a minimum of $9.0 million in offering proceeds, we will allocate a portion of the incoming funds to repay current liabilities, and operating expenses. Such liabilities amount to approximately $2.0 million, including $1.3 million due officers, directors, and other affiliates for compensation, office sharing expenses, and advances.

The balance of about $8.0 million will be available to advance our proposed technology customization and refinement and our licensing effort and general and administrative expenses, including salaries and consulting fees, including compensation to officers and directors. If we obtain up to $19.0 million in gross proceeds from the sale of convertible debt, we will devote the additional funds to expanding and accelerating our implantation of our licensing plan and to payment of the $3.5 million One-time Payment Note to Cell Science and approximate the $3.0 million Working Capital Note payable to OZ Company, both affiliates. Alternatively, in order to maximize cash proceeds from the offering we may seek to accept cancellation of this approximate $3.0 million working capital note with OZ Company as payment for the purchase of convertible debt in the offering.

As we review our business plan and associated capital requirements, we will also review the structure and amount of planned external funding efforts and planned expenditures.

We have no commitments or agreements to complete the above offering.

We expect to eventually generate revenue pursuant to our commercialization and licensing efforts, dependent on obtaining additional capital to fund activities. We cannot assure you, however, that any such financings will be available or will otherwise be made on terms acceptable to us or that our present shareholders might suffer substantial dilution as a result. In addition, we may receive advance payments from joint venture partners, parties to strategic relationships, or sublicensees.

We may also seek additional debt and equity financing to fund payment of additional trade and other obligations incurred and costs of implementing our commercialization and licensing efforts. Our ability to attract debt financing will be substantially impaired by our current lack of both revenues and a robust, viable trading market for our common stock. Accordingly, any debt financing will likely be convertible to common stock, at the lender’s option, at prices discounted to our stock trading price at the time of conversion, which could dilute the interests of existing stockholders. We cannot assure that any such financings will be available, or can be completed on terms acceptable, to us. Any transaction involving the issuance of preferred or common stock, or securities convertible into common stock, would result in dilution, possibly substantial, to our current security holders.

Page 19

Critical Accounting Pronouncements

Our financial statements and related public financial information are based on the application of generally accepted accounting principles in the United States (“GAAP”). GAAP requires the use of estimates, assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risks, and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Our significant accounting policies are summarized in Note 2 of our financial statements included in our July 31, 2023, Form 10-K. While these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our results of operations, financial position or liquidity for the periods presented in this report.

Recent Accounting Pronouncements

See Note 2 in the Notes to the Financial Statements. We have reviewed accounting pronouncements issued during the past two years and have adopted any that are applicable to the Company. We have determined that none had a material impact on our financial position, results of operations, or cash flows for the periods presented in this report.

Page 19

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as “special purpose entities” (“SPE”s).

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”). Based on that evaluation, management concluded that, during the period covered by this report, such internal controls and procedures were not effective due to the following material weakness identified:

·lack of appropriate segregation of duties

·lack of control procedures that include multiple levels of supervision and review

Page 20

·lack of full-time executive personnel to oversee financial reporting and controls

To mitigate these issues, we have an external accountant review all transactions and accounting records and make the appropriate adjustments to the financial statements prior to the review by our external auditor.

Changes in Internal Controls

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended January 31, 2023, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Page 20

PART II - OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

None.

ITEM 1A.RISK FACTORS

Notwithstanding that we are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this Item 1A, in light of the current COVID-19 pandemic, the Company is including the following Risk Factor in its Quarterly Report.

Risks Related to ~~Ukrainian~~World ~~Crises~~Political and Military Exigencies

Russia’s recent military intervention in Ukraine and Hamas’ strikes in Gaza and the international community’s responses have created substantial political and economic disruption, uncertainty, and risk.

Russia’s military intervention in Ukraine in late February 2022, Ukraine’s widespread resistance, and the NATO led and United States coordinated economic, financial, communications, and other sanctions imposed by other countries have created significant political and economic world uncertainty and contributed to worldwide inflation. There is significant risk of expanded military confrontation between Russia and other countries, possibly including the United States. Current and likely additional international sanctions against Russia may contribute to higher costs, particularly for petroleum-based products.

In early October, Hamas melodeonists launched assaults against Israeli citizens in Gaza. Israel has responded aggressively with operations inside Gaza against Hamas. The foregoing events have caused substantial regional instability and world-wide concern and potential involvement. In addition to deadly fighting, the conflict has created large numbers of refugees who are fleeing Gaza.

The Ukraine and Gaza military activities and related actions, responses, and consequences that cannot now be predicted or controlled may contribute to worldwide economic reversals and inflation. In these circumstances, our efforts to commercialize our technology may be delayed or otherwise negatively impacted.

ITEM 2.UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

None

ITEM 5.OTHER INFORMATION

Subsequent Events

Financing Efforts

On February 27, 2024, the Company closed Tranche I of the ongoing private placement sale of $1,030,000 in aggregate principal amount of secured promissory notes bearing interest at 13%, payable in cash or in kind. The notes are payable at maturity in February 2028 (the “13% Convertible Secured Notes”).

The recent closing completes Tranche I of the financing effort commenced in July 2023, near the end of our most recent fiscal year. We then authorized the OZ Company and its owner, John R. Munoz, one of our principal stockholders, as the lead investor (“Lead Investor”), to seek up to $20.0 million in external funding through the sale of 13% Convertible Secured Notes. The obligations under the notes are secured by our assets. The 13% Convertible Secured Notes are convertible to our common stock at $0.50 per share. Upon conversion of the notes, we will issue one warrant for each dollar amount converted, with an exercise price of $0.50 per share for warrants issued on conversion of the first $1.5 million of 13% Convertible Secured Notes issued, an exercise price of $0.75 per share for warrants issued on conversion of the second $3.5 million tranche of 13% Convertible Secured Notes issue, and

Page 21

In connection with this offering, the Company, the Lead Investor, and Inter-M Traders FZ LLE, our single largest record stockholder (the “Principal Shareholder”), agreed to additional terms and conditions, some of which were completed as interim steps during the completion of $1,030,000 in sales, which was styled as Tranche I in the offering, as follows:

In conjunction with the Tranche I Closing, the following corporate governance changes are being implemented.

(a)Until the 13% Convertible Secured Notes are paid in full, the board will be expanded and comprised of seven directors.

(b)Three directors will be designated by the Principal Shareholder, who initially will consist of

(i)Aristotle Popolizio;

(ii)Juan Carlos Garcia La Sienra Garcia; and

(iii)Kimberly Tanami.

(c)Three directors will be designated by the Lead Investor, who initially will be:

(i)Teddy Scott;

(ii)Mitch Kahn; and

(iii)Peter Whitton.

(d)If any designee resigns, is removed, or is otherwise unable to serve, the entity appointing such director will appoint his replacement.

(e)As soon as practical, a majority of the above six directors are to appoint a seventh director. Appointment of the seventh independent director will be subject to approval by the Principal Shareholder. If the event the board is deadlocked, then the current board will nominate three director candidates to the Principal Shareholder, who may select the seventh director.

The Company used the proceeds from the sale of the initial $1,030,000 in 13% Convertible Secured Notes to pay pressing past due and ongoing obligations to our creditors, including $302,369 in compensation to incumbent officers and directors. We propose to use additional available proceeds from the ongoing sale of notes to reduce past due accounts payable, to initiate officer’s and director’s insurance, to pay accrued and ongoing professional fees, general and administrative expenses, science engineering fees sublicensing related expenses, and for general corporate working capital.

Expansion of the Board and Appointment of Directors

As noted above we have agreed to expand our board of directors from five to seven directors and on February 27, 2024, we appointed Teddy Scott, Mitch Kahn, and Kimberly Tamani as directors.

Teddy C. Scott, Ph.D., J.D., has more than 20 years of experience in biotechnology research, intellectual property law and the cannabis industry. Dr. Scott is the founder and former Chief Executive Officer of PharmaCann, where he was Chief Executive Officer from 2014 to 2019, and he was Chief Executive Officer of Ethos Cannabis from 2020 to 2021. Since 2019, Dr. Scott is also a founder and currently serves as a director of SmartHealth Catalyzer, a company that focuses on advancing biotechnology developed at Midwestern universities. Dr. Scott’s legal experience, primarily involving patents, licensing and strategic partnerships focusing on the drug, pharmaceutical and medical device areas, was at law firms including Polsinelli PC from 2006 to 2015, of which he was a shareholder; Howrey LLP, from 2003 to 2006; Katten Muchin Zavis Rosenman, from 2001 to 2003; Wilson Sonsini Goodrich & Rosati, from 2000 to 2001; and McDonnell Boehnen Hulbert & Berghoff, from 1998 to 2000. Dr. Scott earned a BS in Biochemistry from Texas Tech University in 1990; received a Ph.D. in Molecular Biophysics from the University of Texas Southwestern Medical Center in 1997; attended the Southern Methodist University Dedman School of Law from 1997 to 1998; and received his J.D., cum laude, from the Northwestern University Pritzker School of Law in 2000.

Page 22

was a shareholder; Howrey LLP, from 2003 to 2006; Katten Muchin Zavis Rosenman, from 2001 to 2003; Wilson Sonsini Goodrich & Rosati, from 2000 to 2001; and McDonnell Boehnen Hulbert & Berghoff, from 1998 to 2000. Dr. Scott earned a BS in Biochemistry from Texas Tech University in 1990; received a Ph.D. in Molecular Biophysics from the University of Texas Southwestern Medical Center in 1997; attended the Southern Methodist University Dedman School of Law from 1997 to 1998; and received his J.D., cum laude, from the Northwestern University Pritzker School of Law in 2000.

Dr. Scott has been recognized for his leadership in the development of the U.S. cannabis industry by shaping production and development standards for creating high quality, reliable cannabis products. After an extensive international search, the board found a direct skills match with the Company’s objectives to maximize its years of research and development and laboratory testing in cell replication technology and related proprietary equipment, processes and formulation to produce, manufacture and sell cannabis-related (cannabinoid) products.

Mitch Kahn was the Co-Founder and CEO of Grassroots Cannabis, a large private, vertically integrated cannabis operation in the United States, which was purchased by Curaleaf Holdings in 2020. Mr. Kahn co-founded Grassroots in 2014 to provide safe and efficacious cannabinoid products to consumers. Under his leadership, Mr. Kahn led over 1,100 team members across 11 states and obtained more than 60 regulatory licenses in the emerging cannabis sector. Prior to Grassroots Cannabis, Mr. Kahn co-founded Frontline Real Estate Partners, a Chicago-based real estate investment and advisory company with expertise in the acquisition, development, management, disposition, and leasing of commercial real estate properties throughout the United States. The company acquired properties valued at more than $125,000,000 and built a successful brokerage and property management business currently managing more than two million square feet of properties. In addition, to founding Grassroots Cannabis and Frontline, Mr. Kahn co-founded Hilco, a leading real estate restructuring, disposition valuation, and appraisal firm. Mitch served as President and CEO, and grew the business to more than 30 employees and annual revenues in excess of $15,000,000. Mr. Kahn began his career as a transactional attorney focused on real estate and corporate M&A transactions. Before entering his entrepreneurial endeavors, he served as Senior Vice President of Sportmart, growing the company’s footprint from 20 to 70 stores. Mr. Kahn is a graduate of the University of Wisconsin School of Business and received his JD from Northwestern University Law School. Mr. Kahn serves on multiple Boards and is actively involved in numerous charitable and community organizations.

Kimberly Tanami is the CEO and Founder of HPI Canna, a state-of-the-art cultivation, extraction, manufacturing, and distribution facility nestled on 434 acres in New York’s Hudson Valley. Drawing upon more than two decades of extensive executive leadership experience as a CEO and President, Ms. Tanami’s professional trajectory was profoundly influenced by personal tragedy when she lost her sister to epilepsy at the age of 29. This event fueled her determination to explore innovative treatment avenues, including the utilization of cannabis within healthcare frameworks. Under Ms. Tanami’s leadership, HPI Canna has quickly grown into one of New York state’s leading cannabis producers, with a diverse brand portfolio that includes New York’s #1 selling flower brand, Dank, industry heavyweights like Packwoods, and social equity led brands like 40 Tons, Drew Martin, Chef for Higher, Her Highness, and more. HPI Canna embodies Ms. Tanami’s vision of becoming the standard-bearer for New York’s emerging cannabis industry while establishing a healthy and sustainable ecosystem by bringing best-in-class brands to market with innovative partners at every level of the supply chain.

Grant of Options to Directors

With the expansion and appointment of directors as noted above, the Company granted to each of Teddy Scott, Mitch Kahn, Kimberly Tanami, and incumbent directors, Aristotle Popolizio, Peter Whitton and Juan Carlos Garcia La Sienra Garcia, a non-qualified stock option to purchase 240,000 shares of common stock at an exercise price of $1.00 per share. Such options shall be exercisable for seven years. The options shall vest at the rate of 1/12 (i.e., 20,000 shares) per month commencing on the Grant Date, so that all options shall be fully vested and exercisable on the first anniversary of the Grant Date.

Page 23

Option Cancellation and Share Transfer Agreement

Appointment of President and Chief Executive Officer

On April 10, 2024, the Company appointed Dr. Teddy Scott as the President and Chief Executive Officer of the Company. Dr. Scott will serve as the principal executive officer of the Company. Dr. Scott has not been named to serve on any committee of the Board. There are no arrangements or understandings between Dr. Scott and any other persons pursuant to which he was elected as a director. Dr. Scott does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K, and there is no family relationship between Dr. Scott and any of the Company’s other directors or executive officers. We are currently negotiating terms of compensation for Dr. Scott.

Appointment of Chairman of the Board

Also on April 10, 2024, the Company elected Mitch Kahn, as the Chair of the Board of Directors of the Company1. Mr. Kahn has not been named to serve on any committee of the Board. There are no arrangements or understandings between Mr. Kahn and any other persons pursuant to which he was elected as Chairman of the Board. Mr. Kahn does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K, and there is no family relationship between Mr. Kahn and any of the Company’s other directors or executive officers. We are currently negotiating terms for compensation for Mr. Kahn.

Page 24

ITEM 6.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) Exhibits. The following exhibits are either filed as a part hereof or are incorporated by reference. Exhibit numbers correspond to the numbering system in Item 601 of Regulation S-K.

Exhibit Number*		Description of Exhibit
3(i)		Amended and Restated Articles of Incorporation of Bakhu Holdings, Corp. (1)
3(ii)		Amended and Restated By-Laws of Bakhu Holdings, Corp. (1)
4(i)		Certificate of Designation of Series A Preferred Stock (1)
4(ii)		Certificate of Designation of Series B Preferred Stock (1)
4(iii)		Certificate, Amendment or Withdrawal of Designation (Series A Preferred Stock)(17)
4(iv)		Certificate, Amendment or Withdrawal of Designation (Series B Preferred Stock)(17)
10.1		Patent and Technology License Agreement dated December 20, 2018 (2)
10.2		Amended and Restated Patent and Technology License Agreement dated December 31, 2019 (3)
10.3		Strategic Alliance Agreement between CBD Biotech Inc and ICS dated April 17, 2020
10.4		Sublicense Agreement between CBD Biotech and ICS dated April 22, 2020
10.6		Efficacy Demonstration Laboratory Agreement dated June 10, 2020 (5)
10.7		Amendment to Amended and Restated License Agreement dated September 22, 2020 (6)
10.8		Agreement, Assignment Waiver and Estoppel dated September 22, 2020 (6)
10.9		Form of Indemnification Agreement entered into between the Company and Directors Thomas Emmitt, Peter Whitton, Aristotle Popolizio and Euripides Drakes on September 22, 2022, and with Teddy Scott on September 16, 2021(6)
10.10		Assignment and Assumption Agreement dated September 22, 2020 (6)
10.11		Office Cost Sharing Agreement dated September 22, 2020 (6)
10.12		Bakhu 2020 Long-Term Incentive Plan (6)
10.13		Audit Committee Charter (6)
10.14		Consulting Agreement with Fourth and G Holdings, LLC dated June 7, 2021(7)
10.15		Tranche 1 Warrant issued to Fourth and G Holdings, LLC dated June 7, 2021(7)
10.16		Tranche 2 Warrant issued to Fourth and G Holdings, LLC dated June 7, 2021(7)
10.17		First Amendment to Amended and Restated License Agreement dated February 12, 2021(12)
10.18		Second Amendment to Amended and Restated License Agreement dated July 12, 2021(8)
10.19		Consulting Agreement with Damian Solomon dated July 28, 2021(9)
10.20		Consulting Agreement with Sean Akhavan dated July 28, 2021(9)
10.21		First Amendment to Consulting Agreement and Warrants dated September 12, 2021(10)
10.22		Executive Employment Agreement with Teddy Scott dated September 16, 2021(11)
10.23		Third Amendment to Integrated License Agreement dated January 31, 2022(13)
10.24		Employment Agreement dated February 11, 2022(14)
10.25		Consulting Agreement dated February 11, 2022(14)
10.26		Second Amendment to BDC Consulting Agreement dated July 14, 2022(15)
10.27		Promissory Note dated June 23, 2022(15)
10.28		Form of Director Agreement(16)
10.29		Form of Confidentiality and Nondisclosure Agreement(16)
10.30		Form of Indemnification Agreement(16)
10.31		Form of Convertible Secured Promissory Note(17)
10.32		Form of Warrant(17)
10.33		General Security Agreement(17)
10.34		Intellectual Property Security Agreement(17)
14.01		Code of Ethics (6)
21		Subsidiaries (5)
31(i)		CEO certification pursuant to Section 302 of the Sarbanes – Oxley Act of 2002 (18)
31(ii)		CFO certification pursuant to Section 302 of the Sarbanes – Oxley Act of 2002 (18)
32		CEO and CFO certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18)
101**		The following materials from the Company's Annual Report on Form 10-K for the year ended July 31, 2022 formatted in Extensible Business Reporting Language ("XBRL"): (i) the balance sheets (unaudited); (ii) the statements of operations (unaudited); (iii) the statements of cash flows (unaudited); and, (iv) related notes.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema

Page 2425

101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase

(1)Previously filed on Form 8-K on August 22, 2018

(2)Previously filed on Form 8-K on December 27, 2018

(3)Previously filed on Form 8-K on January 14, 2020

(4)Previously filed on Form 8-K on April 27, 2020

(5)Previously filed on Form 8-K on June 12, 2020

(6)Previously filed on Form 8-K on October 1, 2020

(7)Previously filed on Form 8-K on June 16, 2021

(8)Previously filed on Form 8-K on July 12, 2021

(9)Previously filed on Form 8-K on August 2, 2021

(10)Previously filed on Form 8-K on September 14, 2021

(11)Previously filed on Form 8-K on September 21, 2021

(12)Previously filed on Form 10-Q on January 11, 2022

(13)Previously filed on Form 8-K on February 3, 2022

(14)Previously filed on Form 8-K on February 17, 2022

(15)Previously filed on Form 8-K on July 22, 2022

(16)Previously filed on Form 8-K on August 4, 2022

(17) Previously filed on Form 8-K on March 5, 2024

(18) Filed herewith

*	All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.

(b)Financial Statement Schedules. The following financial statements are filed as part of this report:

Unaudited Consolidated Balance Sheets as of January 31, 2024 and the audited balance sheet as of July 31, 2023;	3
Unaudited Consolidated Balance Sheets as of April 30, 2024 and the audited balance sheet as of July 31, 2023;	3
Unaudited Consolidated Statements of Operations for the three-month periods ended January 31, 2024 and 2023	4
Unaudited Consolidated Statements of Operations for the three-month periods ended April 30, 2024 and 2023	4
Unaudited Consolidated Statements of Cash Flows for the three-month periods ended January 31, 2024 and 2023	5
Unaudited Consolidated Statements of Cash Flows for the three-month periods ended April 30, 2024 and 2023	5
Unaudited Consolidated Statement of Stockholders’ Equity (Deficit) for the three-month periods ended January 31, 2024 and 2023	6
Unaudited Consolidated Statement of Stockholders’ Equity (Deficit) for the three-month periods ended April 30, 2024 and 2023	6
Notes to the Consolidated Financial Statements	7

All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the notes thereto.

Page 2526

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BAKHU HOLDINGS, CORP.
Dated: March 25, 2024	/s/ Aristotle Popolizio
Dated: June 18, 2024	/s/ Aristotle Popolizio
	By: Aristotle Popolizio
	Its: Vice PresidentPrincipal Executive Officer
Dated: March 25, 2024	/s/ Juan Carlos Garcia La Sienra Garcia
Dated: June 18, 2024	/s/ Juan Carlos Garcia La Sienra Garcia
	By: Juan Carlos Garcia La Sienra Garcia
	Its: Chief Financial Officer Principal Financial Officer

Page 2627

Filing Compare · Bakhu Holdings, Corp.